Eagle Pharmaceuticals, Inc.
EGRX
EGRX was delisted on the 2nd of October, 2024.
116 hedge funds and large institutions have $667M invested in Eagle Pharmaceuticals, Inc. in 2016 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 45 increasing their positions, 28 reducing their positions, and 26 closing their positions.
61% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 28
54% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $7.55M
4% more capital invested
Capital invested by funds: $640M → $667M (+$27.1M)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
8% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 26
3% less funds holding
Funds holding: 119 → 116 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$43.1M |
| 2 |
Morgan Stanley
New York
|
+$28.8M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$22.8M |
| 4 |
HEC
Hudson Executive Capital
New York
|
+$22M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$9.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$35.1M |
| 2 |
JAM
JW Asset Management
Miami Beach,
Florida
|
-$9.78M |
| 3 |
CCM
Consonance Capital Management
New York
|
-$8.82M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.85M |
| 5 |
State Street
Boston,
Massachusetts
|
-$7.23M |
EGRX Hedge Fund Activity: Q2 2016 in Review
116 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Eagle Pharmaceuticals, Inc. (EGRX) for Q2 2016, worth a combined $667M — up 4.2% from $640M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of EGRX and 24 opened new positions — a net loss of 2 holders — while 28 trimmed existing stakes and 45 added.
The largest buyer was OrbiMed, opening a new position worth an estimated $43.1M. The largest seller was Park West Asset Management, cutting an estimated $35.1M.
- 116 institutional investors held Eagle Pharmaceuticals, Inc. (EGRX) as of Q2 2016, down from 119 in Q1 2016.
- Funds reported $667M of Eagle Pharmaceuticals, Inc. stock for Q2 2016, up 4.2% quarter-over-quarter.
- 24 funds opened new Eagle Pharmaceuticals, Inc. positions in Q2 2016 and 26 closed out, a net change of -2 holders.
- The largest Eagle Pharmaceuticals, Inc. buyer in Q2 2016 was OrbiMed, an estimated $43.1M added.
- The largest Eagle Pharmaceuticals, Inc. seller in Q2 2016 was Park West Asset Management, an estimated $35.1M sold.
Based on aggregated 13F filings for Q2 2016.